目的观察罗哌卡因复合芬太尼用于乳腺区段切除手术中肋间神经阻滞效果及术后镇痛作用。方法选择ASAⅠ或Ⅱ级择期行乳腺肿块区段切除术的患者60例,随机分为两组,每组30例。肋间神经使用0.375%罗哌卡因(Ⅰ组)或0.375%罗哌卡因+芬太尼2μg/...目的观察罗哌卡因复合芬太尼用于乳腺区段切除手术中肋间神经阻滞效果及术后镇痛作用。方法选择ASAⅠ或Ⅱ级择期行乳腺肿块区段切除术的患者60例,随机分为两组,每组30例。肋间神经使用0.375%罗哌卡因(Ⅰ组)或0.375%罗哌卡因+芬太尼2μg/ml(Ⅱ组)。观察两组麻醉起效时间、阻滞完善时间、麻醉维持时间、术后24 h镇痛效果及不良反应,记录麻醉期间RR、MAP、HR及SpO2的变化。结果与Ⅰ组比较,Ⅱ组麻醉起效时间和麻醉阻滞完善时间缩短(P<0.05)、维持时间延长(P<0.01);术后4、8、12 h VAS评分Ⅱ组降低(P<0.01)。两组患者生命体征、不良反应发生率差异无统计学意义。结论芬太尼可增强罗哌卡因肋间神经阻滞麻醉的效果,延长术后镇痛时效。展开更多
Background Breast conserving surgery （BCS） has been the standard surgical procedure for the treatment of early breast cancer. Endoscopic subcutaneous mastectomy （ESM） plus immediate reconstruction with implants is...Background Breast conserving surgery （BCS） has been the standard surgical procedure for the treatment of early breast cancer. Endoscopic subcutaneous mastectomy （ESM） plus immediate reconstruction with implants is an emerging procedure. The objective of this prospective study was to evaluate the clinical outcomes of these two surgical procedures in our clinical setting. Methods From March 2004 to October 2007, 43 patients with breast cancer underwent ESM plus axillary lymph node dissection and immediate reconstruction with implants, while 54 patients underwent BCS. The clinical and pathological characteristics, surgical safety, and therapeutic effects were compared between the two groups. Results There were no significant differences in the age, clinical stage, histopathologic type of tumor, operative blood loss, postoperative drainage time, and postoperative complications between the two groups （P 〉0.05）. The postoperative complications were partial necrosis of the nipple and superficial skin flap in the ESM patients, and hydrops in the axilla and residual cavity in the BCS patients. There was no significant difference in the rate of satisfactory postoperative cosmetic outcomes between the ESM （88.4%, 38/43） and BCS （92.6%, 50/54） patients （P 〉0.05）. During follow-up of 6 months to 4 years, all patients treated with ESM were disease-free, but 3 patients who underwent BCS had metastasis or recurrence -- one of these patients died of multiple organ metastasis. Conclusions After considering the wide indications for use, high surgical safety, and favorable cosmetic outcomes, we conclude that ESM plus axillary lymph node dissection and immediate reconstruction with implants -- the new surgery of choice for breast cancer -- warrants serious consideration as the prospective next standard surgical procedure.展开更多
文摘目的观察罗哌卡因复合芬太尼用于乳腺区段切除手术中肋间神经阻滞效果及术后镇痛作用。方法选择ASAⅠ或Ⅱ级择期行乳腺肿块区段切除术的患者60例,随机分为两组,每组30例。肋间神经使用0.375%罗哌卡因(Ⅰ组)或0.375%罗哌卡因+芬太尼2μg/ml(Ⅱ组)。观察两组麻醉起效时间、阻滞完善时间、麻醉维持时间、术后24 h镇痛效果及不良反应,记录麻醉期间RR、MAP、HR及SpO2的变化。结果与Ⅰ组比较,Ⅱ组麻醉起效时间和麻醉阻滞完善时间缩短(P<0.05)、维持时间延长(P<0.01);术后4、8、12 h VAS评分Ⅱ组降低(P<0.01)。两组患者生命体征、不良反应发生率差异无统计学意义。结论芬太尼可增强罗哌卡因肋间神经阻滞麻醉的效果,延长术后镇痛时效。
文摘Background Breast conserving surgery （BCS） has been the standard surgical procedure for the treatment of early breast cancer. Endoscopic subcutaneous mastectomy （ESM） plus immediate reconstruction with implants is an emerging procedure. The objective of this prospective study was to evaluate the clinical outcomes of these two surgical procedures in our clinical setting. Methods From March 2004 to October 2007, 43 patients with breast cancer underwent ESM plus axillary lymph node dissection and immediate reconstruction with implants, while 54 patients underwent BCS. The clinical and pathological characteristics, surgical safety, and therapeutic effects were compared between the two groups. Results There were no significant differences in the age, clinical stage, histopathologic type of tumor, operative blood loss, postoperative drainage time, and postoperative complications between the two groups （P 〉0.05）. The postoperative complications were partial necrosis of the nipple and superficial skin flap in the ESM patients, and hydrops in the axilla and residual cavity in the BCS patients. There was no significant difference in the rate of satisfactory postoperative cosmetic outcomes between the ESM （88.4%, 38/43） and BCS （92.6%, 50/54） patients （P 〉0.05）. During follow-up of 6 months to 4 years, all patients treated with ESM were disease-free, but 3 patients who underwent BCS had metastasis or recurrence -- one of these patients died of multiple organ metastasis. Conclusions After considering the wide indications for use, high surgical safety, and favorable cosmetic outcomes, we conclude that ESM plus axillary lymph node dissection and immediate reconstruction with implants -- the new surgery of choice for breast cancer -- warrants serious consideration as the prospective next standard surgical procedure.
